Download PDF
Klin Monbl Augenheilkd 2018; 235(04): 469-470
DOI: 10.1055/s-0043-125061
Der interessante Fall
Georg Thieme Verlag KG Stuttgart · New York

Transient Mydriasis under Atomoxetine Treatment: Case Report and Brief Overview of the Literature

Transiente Mydriase unter Atomoxetin-Behandlung: Fallbeispiel und kurzer Literaturüberblick
Ivan O. Haefliger
1   Oculoplastic Surgery, Praxisklinik, Switzerland
,
Marc J. Herz
2   Office, Private Practice, Basel, Switzerland
› Author Affiliations
Further Information

Publication History

received 31 October 2017

accepted 12 December 2017

Publication Date:
18 April 2018 (online)

Also available at
    Permissions and Reprints

Background

Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder that is considered to affect about 5% of the child, adolescent, and adult population [1]. In most cases, ADHD is treated with a combination of behavior therapy and/or medications (i.e., stimulant and non-stimulants drugs) [2]. Atomoxetine (Strattera®), a selective noradrenaline reuptake inhibitor manufactured by Eli Lilly, is a non-stimulant approved medication to treat ADHD [3]. Atomoxetine is commonly used and, around the world, Eli Lilly reported sales of US$885 million in 2016 worldwide (http://www.fiercepharma.com/special-report/10-strattera).

With atomoxetine being a selective presynaptic norepinephrine inhibitor, it has been speculated that atomoxetine could result in an increase in synaptic norepinephrine concentration leading to contraction of the iris dilator radial smooth muscle fibers and mydriasis [4]. This paper reports the case of a possible atomoxetine-induced mydriasis in a child with ADHD.

 

  • References

  • 1 Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics 2012; 9: 490-499
    CrossrefPubMedGoogle Scholar
  • 2 Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother 2014; 48: 209-225
    CrossrefPubMedGoogle Scholar
  • 3 Cascade EF, Kalali AH, Feifel D. Strattera: ups, downs, and emerging uses. Psychiatry 2007; 4: 23-25
    PubMedGoogle Scholar
  • 4 Spiller HA, Hays HL, Aleguas jr. A. Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management. CNS Drugs 2013; 27: 531-543
    CrossrefPubMedGoogle Scholar
  • 5 Caglayan HZ, Colpak IA, Kansu T. A diagnostic challenge: dilated pupil. Curr Opin Ophthalmol 2013; 24: 550-557
    CrossrefPubMedGoogle Scholar
  • 6 Alhatem FJ, Decker DH. Atomoxetine-induced mydriasis. J Child Adolesc Psychopharmacol 2008; 18: 539-541
    CrossrefPubMedGoogle Scholar
  • 7 Bahali K, Ipek H, Yalcin O. et al. Atomoxetine-induced mydriasis in a child patient. Eur Child Adolesc Psychiatry 2014; 23: 1231-1232
    CrossrefPubMedGoogle Scholar